/sitecn/kehuwengzhang/2242.html Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy-锐博生物(ribobio) - 金凤凰娱乐平台,金凤凰娱乐平台注册,金凤凰娱乐平台开户
您当前的位置:首页 > 技术资源 > 客户文章

Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy

发布日期:2017/1/23 13:17:02

期刊名称:Journal of Experimental Medicine


通迅作者:Xu Qi

作者单位:Chinese Academy of Medical Sciences and Peking Union Medical College



The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms ofGLT-1 deficiency may be a novel strategy for treating drug-resistant epilepsy, the underlying molecular cascade remains largely unknown. Here, we show that Hsp90β is up-regulated in reactive astrocytes of the epileptic hippocampus in patients with TLE and mouse models of epilepsyInhibition of Hsp90, but not Hsp70, increased GLT-1 levels. Mechanistically, Hsp90β recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradationHsp90 inhibitor prevents GLT-1 degradation by disrupting the association between Hsp90β and GLT-1. Using a model of TLE, we demonstrated that long-term systemic administration of 17AAG dramatically suppressed spontaneous recurrent seizures and ameliorated astrogliosis. Overall, these results suggest that up-regulation of GLT-1by inhibiting Hsp90β in reactive astrocytes may be a potential therapeutic target for the treatment of epilepsy and excitotoxicity.



版权所有:金凤凰娱乐平台_金凤凰娱乐平台注册_金凤凰娱乐平台开户【唯一授权】 Copyright©2013 Guangzhou RiboBio Co., Ltd.  免费热线:400-686-0075
地址:广州开发区科学城科学大道182号创新大厦C3区13-14层   邮编:510663   粤ICP备05022931号   浏览器建议:IE8.0 1024X768分辨率
主营产品及服务:piRNA  寡核酸  siRNA  miRNA  microRNA   RNAi  shRNA  lncRNA  ncRNA  细胞增殖  生物芯片  高通量测序